Oryzon Genomics S.A. (ORYZF)
- Previous Close
0.0000 - Open
3.0300 - Bid 2.9000 x 36900
- Ask 3.4200 x 312500
- Day's Range
3.0300 - 3.0300 - 52 Week Range
1.4100 - 3.1000 - Volume
5,000 - Avg. Volume
386 - Market Cap (intraday)
234.755M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 13, 2025 - May 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
www.oryzon.comRecent News: ORYZF
View MorePerformance Overview: ORYZF
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORYZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORYZF
View MoreValuation Measures
Market Cap
236.93M
Enterprise Value
240.67M
Trailing P/E
--
Forward P/E
15.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
255.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.81%
Return on Assets (ttm)
-2.61%
Return on Equity (ttm)
-4.34%
Revenue (ttm)
7.36M
Net Income Avi to Common (ttm)
-3.67M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.62M
Total Debt/Equity (mrq)
18.63%
Levered Free Cash Flow (ttm)
-13.75M